Pathway / Endothelial activation & erosion

p27KIP1

CDKN1Bprotein

A cyclin-dependent kinase inhibitor regulating vascular smooth muscle cell proliferation and atherosclerotic plaque remodeling.

Pathway placement

Cascade stepEndothelial activation & erosion

Confidencelow

RationaleCell-cycle inhibitor influencing vascular smooth-muscle proliferation and remodeling.

Also acts inCap degradation / rupture

Druggability

DruggableYes

Known drugs / candidates0

Small-molecule tractableYes

Antibody tractableNo

EnsemblENSG00000111276

Type I vs non-Type I discrimination

ScoresLow-confidence (proxy)

R — rupture / Type-I

C — non-Type-I

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)-24

Non-Type-I axis panel

Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.

No non-Type-I axis evidence retrieved.

Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Serum or plasma

Collection tube

Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)

Method / principle

Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists

Reagent / substrate

Matched anti-target antibody pair (capture + labeled detection)

Platform

ELISA microplate or multiplex (Luminex/MSD)

Turnaround · availability

Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(1)

Impact of oxidized low density lipoprotein on vascular cells.
Atherosclerosis · 2005 · PMID 16288760 · doi